<?xml version="1.0" encoding="UTF-8"?><bill xmlns="http://schemas.gpo.gov/xml/uslm" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://schemas.gpo.gov/xml/uslm uslm-2.0.10.xsd" xml:lang="en"><meta><dc:title>117 H. R. 941 ENR: To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes.</dc:title><dc:type>House Bill</dc:type><dc:creator>U.S. House of Representatives</dc:creator><congress>117</congress><session>1</session><docNumber>941</docNumber><docStage>ENR</docStage><citableAs>117hr941enr</citableAs><citableAs>117 H. R. 941 ENR</citableAs><dc:format>text/xml</dc:format><dc:language>EN</dc:language><dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights><processedBy>Xcential BillDTD to USLM Converter v20210601</processedBy><processedDate>2021-11-20</processedDate><publicPrivate>public</publicPrivate></meta><preface><dc:type>H. R. </dc:type><docNumber>941</docNumber><congress value="117">One Hundred Seventeenth Congress of the United States of America</congress><session value="1">AT THE FIRST SESSION</session><enrolledDateline>Begun and held at the City of Washington on Sunday, the third day of January, two thousand and twenty-one</enrolledDateline></preface><main id="HE00DB281097D43B69184079B47C86705"><longTitle><docTitle>AN ACT</docTitle><officialTitle>To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes.</officialTitle></longTitle><enactingFormula>Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,</enactingFormula><section identifier="/s1" id="H521D005DD3D444098ABBD15574940BA3" class="bill-dtd-OLC"><num value="1">SECTION 1.</num><heading> SHORT TITLE.</heading><content class="indent0">This Act may be cited as the “<shortTitle>Timely ReAuthorization of Necessary Stem-cell Programs Lends Access to Needed Therapies Act of 2021</shortTitle>” or the “<shortTitle>TRANSPLANT Act of 2021</shortTitle>”.</content></section><section identifier="/s2" id="H2571CAF11CC54936BB4E3E2C53210754" class="bill-dtd-OLC"><num value="2">SEC. 2.</num><heading> REAUTHORIZATION OF THE C.W. BILL YOUNG CELL TRANSPLANTATION PROGRAM.</heading><subsection identifier="/s2/a" id="H25CE68ED43234C4983C7BD2141C3C64E" class="bill-dtd-OLC"><num value="a">(a)</num><heading> Advisory Council Meetings.—</heading><content>Subsection (a) of section 379 of the Public Health Service Act (<ref href="/us/usc/42/274k">42 U.S.C. 274k</ref>) is amended by adding at the end the following new paragraph:<quotedContent id="H7827EC9D9C754B1881E6D6352191170E"><paragraph identifier="/s2/a/qB/7" id="H37F32EA6CFF740D09B8D6A725B98BF60" class="bill-dtd-OLC"><num value="7">“(7)</num><content> The Secretary shall convene the Advisory Council at least two times each calendar year.”</content></paragraph></quotedContent>.</content></subsection><subsection identifier="/s2/b" id="H7CCEA0017F1340B7BE59C0C53E991B96" class="bill-dtd-OLC"><num value="b">(b)</num><heading> Increasing Collection.—</heading><paragraph identifier="/s2/b/1" id="H3BF40899CA3D4039910955572D08AF83" class="bill-dtd-OLC"><num value="1">(1)</num><heading> Technical clarification.—</heading><content>Effective as if included in the enactment of <ref href="/us/pl/114/104">Public Law 114–104</ref> (the Stem Cell Therapeutic and Research Reauthorization Act of 2015), the amendment to section 379(d)(2)(B) of the Public Health Service Act (<ref href="/us/usc/42/274k">42 U.S.C. 274k(d)(2)(B)</ref>) in section 2(a)(2) of <ref href="/us/pl/114/104">Public Law 114–104</ref> is amended by inserting “<quotedText>goal of increasing collections of high quality</quotedText>” before “<quotedText>cord blood units,</quotedText>”.</content></paragraph><paragraph identifier="/s2/b/2" id="H751AB02446E54E2E855F8EA76051236B" class="bill-dtd-OLC"><num value="2">(2)</num><heading> Eliminating deadwood.—</heading><content>Subparagraph (B) of section 379(d)(2) of the Public Health Service Act (<ref href="/us/usc/42/274k">42 U.S.C. 274k(d)(2)</ref>) is amended by striking the second and third sentences in such subparagraph.</content></paragraph></subsection><subsection identifier="/s2/c" id="HA57E5F57EABA4772887827A84F71763C" class="bill-dtd-OLC"><num value="c">(c)</num><heading> Periodic Review of State of Science.—</heading><content>Section 379 of the Public Health Service Act (<ref href="/us/usc/42/274k">42 U.S.C. 274k</ref>) is amended by adding at the end the following new subsection:<quotedContent id="HAED8893D4C564E329D15033844C8A5F6"><subsection identifier="/s2/c/qB/o" id="HA783011CF1494E7F8197B86B87171670" class="bill-dtd-OLC"><num value="o">“(o)</num><heading> Periodic Review of State of Science.—</heading><paragraph identifier="/s2/c/qB/o/1" id="H918BDC3060034F99B718860DF30FF6C4" class="bill-dtd-OLC"><num value="1">“(1)</num><heading> Review.—</heading><content>Not less frequently than every 2 years, the Secretary, in consultation with the Director of the National Institutes of Health, the Commissioner of Food and Drugs, the Administrator of the Health Resources and Services Administration, the Advisory Council, and other stakeholders, where appropriate given relevant expertise, shall conduct a review of the state of the science of using adult stem cells and birthing tissues to develop new types of therapies for patients, for the purpose of considering the potential inclusion of such new types of therapies in the Program.</content></paragraph><paragraph identifier="/s2/c/qB/o/2" id="HBD9468C5317E4D18B58A38D5DAF36846" class="bill-dtd-OLC"><num value="2">“(2)</num><heading> Recommendations.—</heading><chapeau>Not later than June 30, 2025, the Secretary shall—</chapeau><subparagraph identifier="/s2/c/qB/o/2/A" id="H0CF33F66930A416180E8A99C99395AF5" class="bill-dtd-OLC"><num value="A">“(A)</num><content> complete the second review required by paragraph (1); and</content></subparagraph><subparagraph identifier="/s2/c/qB/o/2/B" id="HE4DB6F125F9042729A7330CAD85D7091" class="bill-dtd-OLC"><num value="B">“(B)</num><content> informed by such review, submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives recommendations on the appropriateness of the inclusion of new types of therapies in the Program.”</content></subparagraph></paragraph></subsection></quotedContent>.</content></subsection><subsection identifier="/s2/d" id="H9D463F6511BF432DBCB92177F8653A73" class="bill-dtd-OLC"><num value="d">(d)</num><heading> Authorization of Appropriations.—</heading><content>Section 379B of the Public Health Service Act (<ref href="/us/usc/42/274m">42 U.S.C. 274m</ref>) is amended by striking “<quotedText>$33,000,000 for fiscal year 2015 and $30,000,000 for each of fiscal years 2016 through 2020</quotedText>” and inserting “<quotedText>$31,009,000 for each of fiscal years 2022 through 2026</quotedText>”.</content></subsection></section><section identifier="/s3" id="H9585DC1BC9C34DB5A924B99E71875C9E" class="bill-dtd-OLC"><num value="3">SEC. 3.</num><heading> CORD BLOOD INVENTORY.</heading><content><p class="indent0">Subsection (g) of section 2 of the Stem Cell Therapeutic and Research Act of 2005 (<ref href="/us/usc/42/274k">42 U.S.C. 274k</ref> note) is amended to read as follows:</p><quotedContent id="H7D123F77E7B746B48B9C448626820596"><subsection identifier="/s3/qB/g" id="HAC649B14BC244658BA8A14BD20B37E71" class="bill-dtd-OLC"><num value="g">“(g)</num><heading> Authorization of Appropriations.—</heading><content>To carry out this section, there is authorized to be appropriated $23,000,000 for each of fiscal years 2022 through 2026.”</content></subsection></quotedContent>.</content></section><section identifier="/s4" id="H69E5105ADC534C229D007B4C303110FF" class="bill-dtd-OLC"><num value="4">SEC. 4.</num><heading> ADVANCING THE FIELD OF REGENERATIVE MEDICINE.</heading><content><p class="indent0">Section 402 of the Public Health Service Act (<ref href="/us/usc/42/282">42 U.S.C. 282</ref>) is amended by adding at the end the following:</p><quotedContent id="H30EE4CADB6D049CC91972032267B71A3"><subsection identifier="/s4/qB/o" id="H1C003609AC0848EAB92B4A202CCC3535" class="bill-dtd-OLC"><num value="o">“(o)</num><heading> Regenerative Medicine.—</heading><content>The Director of NIH shall, as appropriate, continue to consult with the directors of relevant institutes and centers of the National Institutes of Health, other relevant experts from such institutes and centers, and relevant experts within the Food and Drug Administration, to further the field of regenerative medicine using adult stem cells, including autologous stem cells, therapeutic tissue engineering products, human cell and tissue products, human gene therapies, and genetically modified cells.”</content></subsection></quotedContent>.</content></section><section identifier="/s5" id="HF355B0D617A64B5A927C1098C73518CF" class="bill-dtd-OLC"><num value="5">SEC. 5.</num><heading> GAO REPORT ON REGENERATIVE MEDICINE WORKFORCE.</heading><chapeau>Not later than 2 years after the date of enactment of this Act, the Comptroller General of the United States shall submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report that assesses a specialized health care workforce in the field of regenerative medicine. The report shall include— </chapeau><paragraph identifier="/s5/1" id="H1814B7EC174D4AB49BA7D60655399725" class="bill-dtd-OLC"><num value="1">(1)</num><chapeau> an overview of the current employment levels, in both commercial and academic settings, for—</chapeau><subparagraph identifier="/s5/1/A" id="HCC0EF57F8B8144D4B9C42302BF9D3E07" class="bill-dtd-OLC"><num value="A">(A)</num><content> positions necessary for the collection and transplantation of stem cell therapeutics, including bone marrow and cord blood; and</content></subparagraph><subparagraph identifier="/s5/1/B" id="HCBDA5B9004674465ADCF94ABD8E5B97F" class="bill-dtd-OLC"><num value="B">(B)</num><content> positions in the field of regenerative medicine using adult stem cells and related to product development; </content></subparagraph></paragraph><paragraph identifier="/s5/2" id="HBDE8B4B5D8CE4CBDB7D176EEE6CB3170" class="bill-dtd-OLC"><num value="2">(2)</num><chapeau> the identification of gaps, if any, in the projected workforce capacity for—</chapeau><subparagraph identifier="/s5/2/A" id="H2A6CE89990034180974CEB1CE58BC791" class="bill-dtd-OLC"><num value="A">(A)</num><content> positions described in paragraph (1)(A); and</content></subparagraph><subparagraph identifier="/s5/2/B" id="HD0718323A44E476ABEAEDD52E11148A6" class="bill-dtd-OLC"><num value="B">(B)</num><content> the field of regenerative medicine using adult stem cells, including workforce gaps related to the development of new cellular therapies using adult stem cells;</content></subparagraph></paragraph><paragraph identifier="/s5/3" id="H6C30283217AF42F7B65A31DED974F90E" class="bill-dtd-OLC"><num value="3">(3)</num><content> an overview of the availability of training programs related to the development, refinement, and utilization of adult stem cells, including training on good manufacturing practices for such activities, and the performance of such programs; and</content></paragraph><paragraph identifier="/s5/4" id="H66314EB0D6194791A0950ED9DED2AEDC" class="bill-dtd-OLC"><num value="4">(4)</num><chapeau> recommendations, if any, for improving the workforce capacity related to—</chapeau><subparagraph identifier="/s5/4/A" id="HD4EDEF6736974EC58B87541E4C37FDEB" class="bill-dtd-OLC"><num value="A">(A)</num><content> the positions described in paragraph (1)(A); or</content></subparagraph><subparagraph identifier="/s5/4/B" id="HB6AC38B9AF8C432FB1E3827D302D75EA" class="bill-dtd-OLC"><num value="B">(B)</num><content> the field of regenerative medicine using adult stem cells.</content></subparagraph></paragraph></section></main><signatures><signature><role>Speaker of the House of Representatives.</role></signature><signature><role>Vice President of the United States and President of the Senate.</role></signature></signatures></bill>